Back to Search
Start Over
Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy.
- Source :
- Chinese Journal of Lung Cancer; Jul2022, Vol. 25 Issue 7, p477-481, 5p
- Publication Year :
- 2022
-
Abstract
- Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- Chinese
- ISSN :
- 10093419
- Volume :
- 25
- Issue :
- 7
- Database :
- Supplemental Index
- Journal :
- Chinese Journal of Lung Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 158473493
- Full Text :
- https://doi.org/10.3779/j.issn.1009-3419.2022.101.19